Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
KDIGO 2026 updates anemia care in CKD: evidence-based thresholds for iron therapy, preference for IV iron on hemodialysis, ESA-first approach over HIF-PHIs, individualized Hb initiation, and an ESA maintenance upper Hb target <11.5 g/dL.
Finerenone significantly slows kidney function decline and reduces cardiovascular risk in hypertensive non-diabetic CKD patients, with manageable safety profiles, supporting its therapeutic role beyond diabetes.
A nationwide cohort study reveals that two-thirds of patients with primary hyperparathyroidism exhibit end-organ damage at diagnosis or during follow-up, yet few receive parathyroidectomy, underscoring missed opportunities to reduce morbidi
A predefined subanalysis of EAST-AFNET 4 shows early rhythm control safely reduces cardiovascular events in recently diagnosed AF patients with CKD, with a trend toward greater benefit in this high-risk group.
In a large international prospective cohort of hospitalized patients with cirrhosis, chronic kidney disease was common, clustered with metabolic risk, and strongly associated with acute kidney injury, more decompensation, and higher in-hosp
A post hoc FIDELITY analysis suggests finerenone improves cardiovascular and kidney outcomes across CKM stages and may modestly shift patients toward CKM regression over time.
Higher proteinuria in preeclampsia was linked to greater long-term risk of maternal hypertension and chronic kidney disease, with overall increased risk of cardiovascular disease as well.
In a pre-specified exploratory analysis of SURPASS-CVOT, tirzepatide reduced major kidney events versus dulaglutide in people with type 2 diabetes and cardiovascular disease, mainly by lowering new macroalbuminuria and slowing eGFR decline.
A longitudinal study using Latent Class Analysis identifies four distinct phenotypes of T2D patients developing CKD, highlighting young-onset and middle-aged low-comorbidity groups as primary drivers of healthcare costs.
This review analyzes a latent class trajectory study identifying four clinical phenotypes of T2D-related CKD, revealing that young-onset patients incur the highest longitudinal healthcare costs.
This post hoc analysis of the CREDENCE trial reveals that low-normal sodium intake increases cardiovascular risk in T2D and CKD, a risk significantly mitigated by canagliflozin, while renal protection remains consistent across sodium intake
This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.
This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.
A landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the
This review synthesizes findings on how APOL1 risk variants (G2) drive hypertension and kidney damage through cell-specific mechanisms involving STING activation and endothelin-1 production, offering new precision medicine pathways for high
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
A large-scale prospective study from the UK Biobank reveals that a comprehensive Mediterranean lifestyle—integrating diet, physical activity, and social connectivity—significantly reduces the risk of incident chronic kidney disease by up to
A large-scale prospective study from the UK Biobank reveals that high adherence to a Mediterranean lifestyle, including diet, physical activity, and social habits, significantly reduces the risk of developing chronic kidney disease over an
A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement
Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st